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Proprotein convertases (PCs) are highly specific proteases required
for the proteolytic modification of many secreted proteins. An
unbalanced activity of these enzymes is connected to pathologies
like cancer, atherosclerosis, hypercholesterolaemia, and infectious
diseases. Novel protein crystallographic structures of the prototyp-
ical PC family member furin in different functional states were
determined to 1.8–2.0 Å. These, together with biochemical data and
modeling by molecular dynamics calculations, suggest essential ele-
ments underlying its unusually high substrate specificity. Furin
shows a complex activation mechanism and exists in at least four
defined states: (i) the “off state,” incompatible with substrate bind-
ing as seen in the unliganded enzyme; (ii) the active “on state” seen
in inhibitor-bound furin; and the respective (iii) calcium-free and (iv)
calcium-bound forms. The transition from the off to the on state is
triggered by ligand binding at subsites S1 to S4 and appears to
underlie the preferential recognition of the four-residue sequence
motif of furin. The molecular dynamics simulations of the four struc-
tural states reflect the experimental observations in general and
provide approximations of the respective stabilities. Ligation by
calcium at the PC-specific binding site II influences the active-site
geometry and determines the rotamer state of the oxyanion hole-
forming Asn295, and thus adds a second level of the activity
modulation of furin. The described crystal forms and the observa-
tions of different defined functional states may foster the develop-
ment of new tools and strategies for pharmacological intervention
targeting furin.
serine-protease | activation | specificity | conformational transition
Furin belongs to the family of highly specific, calcium-dependentproprotein/prohormone convertases (PCs) (1), endoproteinases
that feature a catalytic domain of homology to subtilisin and acti-
vate a large number of secreted proteins by limited proteolysis.
Furin is a type I transmembrane serine-protease that is ubiqui-
tously expressed and cycles from the trans-Golgi network to the cell
membrane, as well as through the endosomal system. In mammals,
the PC family embraces seven members that cleave after multiple
basic residues (furin, PC1, PC2, PC4, PACE4, PC5/6, and PC7)
and at the general cleavage site (R/K)Xn(R/K)↓ (where “↓” rep-
resents the scissile peptide bond), with furin preferentially recog-
nizing the motif R-X-K/R-R↓ (2). This highly sequence-specific
cleavage is essential for the activation of numerous PC substrates
(2). The PCs are also involved in a large number of pathologies,
including bacterial and viral infections, as well as cancer and me-
tastasis. Therefore, these enzymes are intensely investigated as
drug targets (3), using for example, peptide-derived compounds
(4–9), nonpeptidic small molecule compounds (10, 11), and pro-
tein-based inhibitors (12–15).
Different crystal structures of the inhibitor-bound murine (16)
and human (6, 17) enzyme, together with structural studies of the
yeast homolog Kex2p (18, 19) and modeling approaches (9, 20),
gave hints of how substrates and substrate-derived inhibitors
bind with high specificity to furin and to the PCs, but suffer from
the lack of structural information of the unliganded enzyme. The
commonly accepted notion is that the PCs bind their cognate
substrates via recognition at several subsites, typically involving
multiple tight contacts and hydrogen bonds. Catalytic efficiency,
however, in addition to strong and fast binding of substrate, re-
quires rapid chemical transformation and fast release of product.
The chemical reaction catalyzed by furin and other proteases—
the hydrolysis of the scissile peptide bond—often involves limited
structural changes of the active site residues, which are unlikely to
perturb remote substrate-binding subsites of the enzyme. Furin
has an extended substrate-binding area where typically all speci-
ficity-determining residues are located N-terminal to the scissile
peptide bond, suggesting that the C-terminal segment is more
loosely bound and may dissociate readily after hydrolysis. Potent
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noncovalent inhibitors are characterized by very slow off-rates,
a feature that may apply to very tight binding substrates that are
poorly cleaved as well, and can thus act as efficient inhibitors as
those, for example, shown in other protease families for the slowly
hydrolyzed dipeptidyl peptidase IV substrate diprotin A (21).
The high substrate selectivity and enzymatic activity of furin,
and its strict Ca2+ dependence, demand a structure-based expla-
nation. Although Ca2+ is not involved in the catalytic cycle per se,
all PCs require calcium for their enzymatic activity (17, 22, 23).
One more distinctive feature of furin in the protease family is
its very limited reactivity toward typical covalent inhibitors of
serine proteases, like diisopropylfluorphosphat (DFP) and phe-
nylmethylsulfonylfluorid (PMSF). Interestingly, the spatial re-
strictions at and around the catalytic serine residue 368 of furin
are structurally reminiscent of typical trypsin-like proteases. This
similarity is especially evident for the deep S1 pocket selecting for
basic amino acid side chains at P1, the β-strand of the enzyme
(Ser253-Gly255 in furin vs. Ser214-Gly216 in trypsin), displaying
antiparallel β-sheet–like contacts with a peptidic substrate and a
typical hydrophobic tryptophane (Trp254 in furin vs. Trp215 in
trypsin) in its center. Therefore, one would expect a similar reactivity
of furin against nonselective, covalent inhibitors that do not specif-
ically interact with the different specificity pockets, but probe the
nucleophilic catalytic site serine residue; however, this has not been
observed. Furin is also completely inert against typical monobasic
trypsin-substrates (our own observations and those, for example, in
refs. 22 and 24). This is observed even though (i) the P1 require-
ments of the two enzymes are comparable, (ii) furin accepts different
residues at its S2-pocket, and (iii) its S3-pocket is not very specific.
To address the above questions and to find out how the high
negative-charge density within the active site cleft of furin is stabilized
in its ligand-free state, we have studied the structure of the unliganded
enzyme as well as of different Ca2+ and inhibitor-bound forms by
X-ray crystallography at high resolution. Comparison of the different
crystal structures together with solution studies and molecular dy-
namics (MD) simulations give hints of the enzymatic mechanism and
the unique features of this central regulatory endoproteinase.
Results
Inhibitor-Induced Structural Changes of the Active-Site Cleft.Human
furin was crystallized in its unliganded state, its structure solved
by molecular replacement (MR), and refined up to 1.8-Å reso-
lution at high quality (Fig. 1A and Table S1). Structure align-
ments of unliganded furin with the inhibitor-bound human and
mouse furin structures demonstrated high overall similarity
(Cα-rmsd of 0.22 Å and 0.28 Å, respectively). A close inspection
of the active-site residues and the substrate-binding cleft, how-
ever, revealed substantial differences.
To directly investigate structural changes occurring upon sub-
strate binding in identical crystal forms, we soaked the unli-
ganded crystals with the substrate analogous, noncovalent inhibitor
m-guanidinomethyl-phenylacetyl-Arg-Val-Arg-(4-amidomethyl)-
benzamidine (MI-52, #26 in ref. 4). The active-site cleft of furin is
oriented toward large solvent channels in these crystals, enabling
the binding of large peptidic compounds to the protease unper-
turbed by crystal packing. The crystal structure was refined at a
resolution of 2.0 Å (Table S1). A residue-wise comparison of
unliganded and inhibitor-bound forms revealed a number of sig-
nificant structural changes (Fig. S1A). Hotspots of conformational
changes include the catalytic residues His194, Ser368, Asn295 of
the oxyanion hole, the sodium binding site (Thr309 and Ser316),
and residues in direct contact with the inhibitor peptide (e.g., the
region Ser253–Pro256, the alignment template). Mapping of the
Cα displacement to the surface of the structure induced by in-
hibitor binding revealed a concerted local rearrangement at the
substrate-binding cleft (Fig. 1B and Fig. S1B). These displace-
ments propagate with diminishing amplitude to the core of the
protease (Fig. S1C). The catalytic residues and the alignment
template are well defined in the electron-density maps (Fig. S2 A
and B) and characterized by low flexibility.
A structural comparison of the substrate-binding region in-
deed revealed two distinct conformational states for furin (Fig. 2A
and Fig. S3A). In contrast, the homologous unspecific protease
subtilisin showed a high overall structural similarity (Cα rmsd of
0.24 Å) of the unliganded structure [PDB ID code 3UNX (25)] and
the subtilisin–eglin-c complex [PDB ID code 1CSE (26)] as well as
identical conformations of the active site cleft (Fig. 2B and Fig. S3B).
A principal component analysis (PCA) was carried out to gain
further insight into the structural modifications induced by inhibitor
binding and their relationship with furin’s homologous proteins. To
allow a direct comparison between furin and the closely related pro-
tease subtilisin Carlsberg, a common core of 191 residues was selected
to perform the PCA on their Cα atoms. Projecting the crystallo-
graphic structures on the first principal component, which captures
more than 80% of the variance, shows a clear separation among the
furin structures with and without ligand-bound conformations (Fig.
3A), but not among the subtilisin Carlsberg structures, where both
unliganded and inhibitor-bound conformations exhibit closer simi-
larity to the furin inhibitor-bound structures. These observations
prompted us to consider the first principal component as an appro-
priate metric to monitor the unliganded and inhibitor-bound states. A
detailed inspection revealed that the conformation of residues proxi-
mal to the alignment template and the active site of subtilisin and
furin are similar in the ligand-bound state (overall Cα rmsd of 0.38 Å)
(Fig. 2C and Fig. S3C): specifically, the rotamers of Ser221 of sub-
tilisin and Ser368 of furin, respectively. Conversely, the unliganded
conformations of both enzymes differ and reflect the structural tran-
sition in furin absent in subtilisin. Interestingly, the PCA covariance
matrix unveils a concerted movement between the alignment template
(Ser253–Pro256), residues neighboring the sodium binding site (314–
317), and the oxyanion hole (290–297 and 365–369) again.
The unliganded structure of furin has the side chain of Ser368
rotated 180° away from the S1 pocket and the scissile peptide bond,
as defined in the dec–RVKR–cmk complex structure (16), altering
the interaction geometry of the catalytic triad and disrupting the
essential hydrogen bond to His194. However, a nucleophilic attack at
the scissile peptide bond requires a conformation, as observed in the
inhibitor-bound structure. The rotamer of Ser368 as observed in the
unliganded structure can thus not enable substrate processing. In-
terestingly, the rotameric state of Asn295 in the unliganded and the
ligand-bound forms is largely identical as long as the Ca2+-(II) site is
occupied (seeCalcium-Dependent Activity Regulation of Furin, below).
The loss of the hydrogen bond between Ser253-OH and the
carbonyl-O of Ser368 appears to facilitate the reorientation of
Fig. 1. Analysis of substrate induced structural rearrangements of furin.
(A) Overall structure of human unliganded furin (catalytic and the P-domains
are in gold and blue, respectively). The catalytic residues (cyan stick model), the
substrate binding pockets (labeled S1–S5), and bound ions (purple sphere, Na+;
green spheres, Ca2+) are indicated. (B) The Cα-displacement values (intervals
<0.3 Å, 0.3–0.8 Å, and >0.8 Å are highlighted in cyan, yellow, and magenta,
respectively) were mapped to the molecular surface.








Ser368 in unliganded furin (Fig. 2A and Fig. S3A). In addition,
binding of peptide chains to the active-site cleft of furin requires
a specific orientation of the alignment template, enabling char-
acteristic backbone interactions and a P1–side-chain recognition.
These interactions are incompatible with the unliganded structure
(Fig. 2A and Fig. S3A). Furthermore, steric clashes between ligand
and the enzyme would occur, especially at P1 and P4. In conclu-
sion, the catalytic residues and the substrate-binding region adopt
an inactive conformation in the unliganded furin structure, repre-
senting an “off” state. By binding of the substrate-analog inhibitor
MI-52, the enzyme switches to a catalytically active “on” state.
MD Calculations Show Switching Between the On and Off States.
Next we assessed the stability of the unliganded and inhibitor-
bound conformations by performing MD simulations. For this
purpose, furin and subtilisin were simulated in three different con-
ditions: (i) an unliganded state, (ii) an inhibitor-bound state, and
(iii) an inhibitor-removed state (protein in its inhibitor-bound con-
formation with the inhibitor molecule deleted). Histograms collected
from projecting MD trajectories on the first principal component
show that for furin, the inhibitor-removed state drifts away from its
initial inhibitor-bound conformation. It relaxes toward a conforma-
tion that resembles the crystallographic unliganded conformation
and approaches the relaxation state reached by simulations of furin’s
unliganded state (Fig. 3B). In contrast the inhibitor-bound
simulations show that the furin–MI-52 complex is highly stable,
sampling conformations around its crystallographic pose. Notably,
furin simulations in its unliganded state eventually visit the ligand-
bound conformation, thereby suggesting that the latter is a ther-
mally accessible state. In subtilisin, all three systems retain their
crystallographic conformations and sample inhibitor-bound–like
structures (Figs. 2B and 3B and Fig. S3B). These results suggest that
in furin, but not in subtilisin, a fraction of the ligand binding energy
is spent in transforming the enzyme from an off state to an on state.
Prompted by these observations, we reanalyzed the melting
temperatures (Tm) of furin–inhibitor complexes and their de-
pendence on the Ki-values (6). In a semi-logarithmic represen-
tation of the data, an apparent linear relationship between pKi
(range 6.4–11.3) and Tm can be found. Interestingly, by extrap-
olation to pKi-values < 6, Tm falls below the value observed for
unliganded furin. We reason that the dependence of melting
temperature and stability on ligand affinity rests on two opposing
factors: a gain in bonding interactions and energy with increasing
affinity and a loss by the conformational switch with all ligands,
such that the latter prevails with weakly binding ligands.
Specific Entities Define the Structural Difference Between the Two
Conformational States.Comparisons of the unliganded and inhibitor-
bound crystallographic structures provide insight regarding to the key
structural features that characterize the on state. Different alignment
Fig. 2. Structural comparison of substrates binding to the active sites of furin and to subtilisin Carlsberg. (A) Structural alignment of selected residues of unliganded
furin (yellow carbons) and inhibitor-bound furin (gray carbons; inhibitor: ball-and-stick). Steric clashes between bound inhibitor/substrate and unliganded furin are
highlighted as red line patterns. (B) Structural alignment of unliganded subtilisin (orange carbons) and inhibitor-bound subtilisin (green carbons). (C) Structural
alignment of inhibitor-bound subtilisin (green carbons) and furin (gray-colored stick model). Important interactions are always highlighted by dashes.
Fig. 3. PCA. (A) Projections of furin (squares) and subtilisin Carlsberg (triangles) on the first two principal components. Only human furin structures (green)
were used to compute the covariance matrix. Murine furin structures (blue) are shown for comparison only. Open and closed markers represent unliganded
and inhibitor-bound structures, respectively. (Inset) The proportion of the structural variation encoded within each principal component. (B) Histograms of
MD-simulation frames projected on the first principal component for each simulated system: furin unliganded state (red), furin inhibitor-bound (blue), furin
inhibitor-removed (green), subtilisin unliganded state (black), substilisin inhibitor-bound (cyan), and subsitilisn inhibitor-removed (magenta). Projections of
the crystallographic structures are shown on the x axis as in A. (Inset) Examples of MD trajectories.
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template configurations allow hydrogen bond formation between
Ser253γOH and the carbonyl oxygen of Ser368 in the on state,
whereas this interaction is absent in the off state. This interaction
prompts a Ser368 side-chain rotation of 180° away from the S1
pocket, thereby altering the interaction geometry of the catalytic
triad. The MD simulations support this mechanism because, in the
furin–inhibitor complex, the Ser253γOH–Ser368O hydrogen bond is
observed 88% of the time, considering all repetitions (SI Materials
and Methods), as a part of a dynamic process, and the rotameric state
of Ser368 is stable in the experimentally observed conformation (Fig.
S4A). In contrast, in the furin unliganded system this hydrogen bond
is practically never observed (1% of the time) and the distribution of
Ser368 χ-angle is bimodal, suggesting a dynamic equilibrium be-
tween the two orientations. Interestingly, the dynamic behavior of
Thr367 appears to be also related to the on and off states. The
Thr367 χ1 dihedral angle (Fig. S4B) displays a single orientation in
the liganded state corresponding to the crystal structure, whereas the
unliganded form shows, as for Ser368, two stable orientations.
However, only one of these orientations corresponds to that ob-
served in the crystals. The MD data suggest that Thr367 χ1 also
samples an orientation where its hydroxyl group approaches the S1
pocket and the Asn295’s side chain.
Conformational changes are also transduced to the single so-
dium binding site of the protease (Fig. S5). In the unliganded
structure the sodium ion is coordinated by the carbonyl oxygens
of Thr309, Ser311, and Thr314, the hydroxyls of Thr314 and
Ser316, as well as one water molecule, in the preferred octahedral
coordination. Upon inhibitor binding, the coordination changes to
a tetragonal-pyramidal geometry that is less frequently observed.
The side-chain rotations of Ser316 and Thr309 result in breakage
of the coordinative bond to the sodium ion and loss of the hy-
drogen bond between these residues, indicating a switch from a
lower (unliganded form) to a higher (liganded form) energy state.
Accordingly, in the MD simulations of the unliganded system the
rotameric state of Ser316 is highly stable and the Ser316γOH–
Thr309γOH interaction is relatively well conserved, being present
50% time in a dynamic fashion considering all repetitions.
Reaction of Furin with Nonspecific Inhibitors. Previous studies had
demonstrated a lack of reactivity of furin for nonspecific covalent
serine protease inhibitors (22). We have reanalyzed here the ini-
hibitory potency of DFP, 4-(2-aminoethyl)benzensulfonylfluorid
(AEBSF), and PMSF. All three inhibitors readily inhibited the ac-
tivity of the two prototypical serine proteases, trypsin and subtilisin,
to below 3% of their original activity, but did not significantly affect
the activity of human furin (SI Materials and Methods). As
modeling excluded steric reasons, the failure of these inhibitors to
bind may reflect the electronic properties and activation state of
furin’s active site, and thus represent an electrophilic probe and
measure for the reactivity of the protease.
Calcium-Dependent Activity Regulation of Furin. Previous studies
have shown that the activity of furin is dependent on the pres-
ence of calcium (22). To investigate its role in activity regulation
and substrate binding, we soaked unliganded furin crystals with
EDTA, and analyzed and refined the structure to 2.0-Å resolution
(Table S1). To our surprise, only the Ca2+-(II) and Ca2+-(III) ions
(Fig. 1A) were removed by addition of the strong calcium chelator,
suggesting different affinities of the three calcium binding sites.
We further analyzed their anomalous diffraction at defined con-
centrations of Ca2+ (Table S2), finding decreasing affinities in the
order Ca2+-(I) > Ca2+-(II) > Ca2+-(III) (Fig. S6 A–D).
A structural comparison of unliganded furin crystals soaked
with either EDTA or grown in the presence of 1 mM Ca2+
revealed almost an identical result in the PCA (Fig. 3A) and in
the Cα overlay (rmsd 0.09 Å) (Fig. S7). In addition, the distri-
bution of B-factors of surface-exposed residues is highly similar.
However, a detailed inspection of the active-site residues revealed
differences at the Ca2+-(II) binding site. Although the calcium
ligands Asp258, Asp301, and Glu331 undergo only slight changes
upon removal of Ca2+-(II), the side chain of Asn295 displays a
different rotamer and loses its role as central component of the
oxyanion hole, where it forms a hydrogen bond to and thus po-
larizes the carbonyl oxygen of the scissile peptide (Fig. S6 E and
F). In the Ca2+-(II)–free state the side chain of Asp258 may be
protonated. It moves slightly toward the position of the previously
bound calcium ion such that it now forms a hydrogen bond with
the flipped side-chain amide of Asn295. Charging of the Ca2+ site
pushes Asp258 away and causes a reorientation of the Asn295 side
chain to the catalytically competent conformation. Distortion of
the oxyanion hole explains the calcium requirement for catalysis.
EDTA-soaked crystals were also subjected to a second soaking
step with MI-52 to study the impact of ligand binding (Table S1).
Interestingly, the observed changes triggered by the inhibitor are
nearly identical to those observed in the Ca2+-(II)–bound forms
(Fig. S6E). The conformation of the Ca2+-(III) ligands are iden-
tical in presence and absence of Ca2+ (Fig. S6D).
A series of five independent MD simulations was performed
on the EDTA-soaked unliganded furin structure to evaluate the
consequences of the empty Ca2+-(II) site on dynamics. These sim-
ulations were carried out considering two Asp258 protonation states.
Interestingly, in simulations where Asp258 is protonated, its side-
chain orientation corresponds to that observed in the crystal, but
showed a second conformation in its charged state (Fig. S4C). The
experimentally observed orientation of the Asn295 side chain in
Ca2+-(II)–free unliganded furin crystals was only seen as a minor
species in MD; it mainly sampled conformations more similar to
those observed in the Ca2+-(II)–bound state (Fig. S4D). Neverthe-
less, prominent differences were observed in Gly255 and in the
catalytic triad geometry. The empty ion pocket allows more rota-
tional freedom to Gly255’s ψ angle (Fig. S4E). Because Gly255 is a
key element of the alignment template, its structural alteration im-
pairs substrate recognition. Although in this case the MD simula-
tions and the crystallographic observations do not reinforce each
other in detail, they both suggest that Ca2+-(II) stabilizes substrate
binding and processing.
Discussion
The herein described crystals of unliganded furin allowed us to
investigate conformational rearrangements triggered by substrate
and calcium binding to PCs. These studies revealed two activity-
switches affecting the functionality of the active site dependent
upon substrate and calcium, respectively. Comparing the struc-
tures of unliganded and inhibitor-bound furin, we observe a sig-
nificant structural rearrangement of the substrate-binding cleft
without alteration of the global fold of the protease, which pro-
vides a structural framework and should be highly conserved in
orthologs of this enzyme as well (6, 16, 17). The active-site cleft
shuttles between two structurally well-defined states of the en-
zyme, the inactive off and the active on states.
Furin and the bacterial subtilisin show highly conserved
catalytic domains in their inhibitor-bound states, but differ
significantly in their unliganded forms. In addition, inhibitor-
free subtilisin displays a relatively high structural flexibility at
the S1 and S4 pockets (27), indicating plasticity and hence fa-
cilitating the binding of different sequence motives. In furin,
the substrate-binding area is characterized by low B-factors,
indicating a rigid framework in both the unliganded and the
ligand-bound forms. Ligand binding and rearrangements of the
S1 and S4 sites and the main chain are cooperatively coupled
with the active-site residues, in particular Ser368. The observed
inactivity of furin with nonspecific covalent inhibitors that
probe the nucleophilicity of the active site Ser368 but lack S1 to
S4 substituents reflects this cooperativity.
We suppose that the switch between two rigid conformations
requires precise bonding interactions and restricts substrate








binding to a well-defined sequence motif. Exceptional substrate
specificity is a hallmark of furin and other PCs, and hence a
fundamental requirement of a functional secretory system and
for cellular homeostasis (2).
The MD simulations demonstrate relaxation of the inhibitor-
bound on state to the unliganded conformation following ligand
dissociation (Fig. 3B). This finding shows that furin can switch
between these two states and that the active on state of furin is
less stable and requires the presence of a bound substrate or
substrate-like inhibitor. This finding is in line with our extrapo-
lation of the Tm to weak Ki-values that also suggests a lower
structural stability of an inhibitor-free on state of furin. The MD
simulations indicate that the on state is already visited in the
ligand-free condition, thus suggesting that the substrate may bind
directly to this state without energy expenditure (Fig. 3B). However,
in such a scenario a better performance would be expected from the
nonspecific covalent inhibitors of the serine protease family (22) (SI
Materials and Methods). This evidence argues in favor of a mecha-
nism, where the energy cost of the activation and stabilization of the
protease in its on state is paid by ligand binding. Further support to
this mechanism comes from the observed change in the co-
ordination sphere of the sodium binding site in furin that is linked to
inhibitor binding. The previously noted rather atypically bent or
kinked conformation of the Arg-side chain at P4 (16, 20), which also
corresponds to an energetically unfavorable yet well-defined con-
formation, may also consume some of the binding energy. In ad-
dition, a general stabilization of furin by inhibitor binding was
demonstrated previously (6) and is recapitulated in the MD simu-
lations, showing a substantially narrower distribution of conformers
of the complex compared with the unliganded forms (Fig. 3B).
These considerations are relevant for the catalytic properties
of furin. The requirement of energy to convert the protease from
the off to the on state affects substrate specificity, because only
ligands with sufficient binding energy may activate the enzyme.
It also nicely explains the efficient cleavage of Arg-X-X-Arg↓
substrates that occupy the S1 and S4 sites. These are highly
preferred to X-X-(Lys/Arg)-Arg↓ substrates. Monobasic pep-
tides are even completely inert against proteolysis by furin (24,
28). A substrate-induced conformational shift might also influ-
ence the catalytic efficacy of the protease. Extensive protease–
substrate interactions as described for furin usually result in large
binding energies, and hence slow off-kinetics of the formed
products and, in essence, in slow turnover of the substrate. A
structural rearrangement could absorb some of the energy of
substrate binding; it might reduce the net binding energy and
thus allow for the observed fast kinetics of the PCs (28) that is
comparable, for example, to the much less-specific subtilisin.
Two principal mechanisms may govern the transition from the off
to the on state of furin: that is, induced fit triggered by ligand
binding or conformational selection (Fig. 4). In the absence of ex-
perimental kinetic data, the MD simulations may provide a hint for
the latter, as the ligand-removed form relaxes toward the unli-
ganded structure within the first 20 ns and the unliganded form
shows a relatively broad distribution of conformers (Fig. 3B). In
addition, the χ1 angle histograms of the amino acid side chains with
alternative torsions in unliganded and liganded forms show mostly
bimodal distributions in the former, in accord with conformational
equilibria (Fig. S4).
Ligand-induced structural changes in proteases have been found
and intensely studied by structural and MD studies in the protea-
some, where only precisely defined enzyme main-chain peptidic
ligand interactions induce opening and closing of the substrate-
binding cleft, whereas other ligands do not have this effect. In ad-
dition, a variant of the proteasome, the immune proteasome, does
not shuttle between different conformers and remains in the enzy-
matically competent conformation in the ligand-free form. This
finding was interpreted as an important factor, contributing to the
superior activity of the immune proteasome (29).
Another example of a protease shown to switch the conformation
upon interaction with substrate (or inhibitor) is the αI-tryptase
variant rHTαGI, which exhibits equilibria between the two states
(30). Comparing furin to the 3C protease family, which embraces
cysteine-type proteases with trypsin-like fold—including for exam-
ple, tobacco etch virus protease or human rhinovirus 14 3C protease
[HRV14, PreScission protease (31)]—shows that the conformation
of the catalytic residues is here unaffected by substrate binding,
pointing to a different mechanism to achieve the required high
specificity. Additional reports on substrate-induced activation of
proteases regard, for example, the caspase family (32, 33), where a
more complex mechanism (also depending on dimerization, pro-
teolytic cleavage, and conformational change) regulates their
cleavage activity, and the oligopeptidase family (34), where [in es-
sence similar to furin’s regulation by Ca2+-(II)] structural alterations
in the vicinity of the oxyanion hole of the protease are described.
We also studied the three binding sites of calcium observed for
human furin (17). Whereas Ca2+-(I) and Ca2+-(III) are con-
served in bacterial subtilases, Ca2+-(II) is specific for furin and
the other PCs (17, 23). Ca2+-(I) is tightly bound and fulfils a
stabilizing, structural role in subtilisin and in furin. Ca2+-(II) and
Ca2+-(III) show a less-tight interaction with binding strengths of
the three sites in the order Ca2+-(I) > Ca2+-(II) > Ca2+-(III).
The crystal structures without Ca2+-(II) do not indicate a sig-
nificant effect on the geometry of inhibitor binding, except for an
alternative rotamer of Asn295 and an inoperable oxyanion hole.
Thus, Ca2+-(II) is mainly responsible for stabilizing the catalyt-
ically competent state of furin (22).
The dynamic data of the MD simulations suggest, however,
that with an empty Ca2+-(II) pocket substrate binding has to pay
an extra energetic penalty because of the destabilization of the
Gly255 backbone and the side chain of Asp258 (Fig. S4 C–E).
Interestingly, when Asp258 was protonated, together with an
empty Ca2+-(II) pocket, its crystallographic pose was retained
and the effect on Gly255 disappeared (Fig. S4 C–E). Here the
MD simulations do not reflect the crystallographic data in detail,
demonstrating only a partial reorientation of the Asn295 side chain
in the Ca2+-(II)–free form (Figs. S3 and S4D). A closer inspection
of furin and subtilisin offers a possible explanation for this apparent
failure. In subtilisin Asn155’s orientation is reinforced by a hydro-
gen bond with Thr220Oγ, equivalent to Thr367 in furin. In the
subtilisin simulations, the Asn155Nδ–Thr220Oγ hydrogen bond was
indeed observed over 95% of the whole simulated time.
In accord with subtilisin and the murine furin structure [PDB ID
code 1P8J (16)], crystallized in the presence of a covalent inhibitor,
the Asn295 orientation is reinforced by establishing a hydrogen
Fig. 4. Schematic energy landscapes according to different scenarios. Furin,
in an inhibitor-free condition (red solid line), resides most of the time at the
bottom of an energy well adopting an off-state conformation, whereas its
catalytically active on state is not energetically stable. In the presence of an
inhibitor (blue solid line), the energy landscape is modified and the furin–
ligand interaction stabilizes the on-state conformation. Furin and the ligand
are represented as continuous gray/red and cyan surfaces, respectively. Black
dashed lines represent the corresponding energy states.
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bond with Thr367. In both proteins, murine furin and subtilisin, the
Asn295–Thr367 interaction is achieved by positioning the Thr367
side chain with a χ1 dihedral angle at ∼60°. Strikingly, this ap-
parently crucial orientation is very well observed in the human
furin simulations (Fig. S4B). The failure to observe the Asn295
conformation in our simulations may be because of the fact that
Thr367 was not initially oriented to support this interaction. Re-
markably, further stabilization of Asn295’s crystallographic pose
was achieved in MD simulations of the furin unliganded structure,
when the interaction between Thr367 and Asn295 was artificially
set as a starting condition (Fig. S4D).
The activity of furin seems to be controlled by two intertwined
mechanisms, including (i) a calcium-triggered switch mediated
by the Ca2+-II site and (ii) a conformational on/off switch, both
connected to substrate specificity and catalytic efficiency. This
rather elaborate activation mode is probably essential for the
unusually high substrate selectivity seen of furin and the other
highly homologous PC-family members (20). The described two-
fold activation mechanism and the underlying structural basis offer
opportunities for activity modulation of either individual PCs or
multiple family members.
Materials and Methods
Expression, Crystallization, and Structure Determination. Details regarding the
plasmids, the expression system, purification procedure, and functional
analysis used for human furin were described previously (17) and are also
given in SI Materials and Methods. Crystals of human furin were grown in
sitting drops mixing equal volumes of the protein solution (∼9 mg/mL) and
crystallization solution [100 mM Mes, 200 mM K/NaH2PO4, pH 5.5–6.0, 3–4 M
NaCl, and 3% (vol/vol) DMSO]. The reservoir contained 3–4 M NaCl. For in-
hibitor binding studies, the crystals were soaked with MI-52 (4) and for the
calcium-studies the crystals were soaked with EDTA and Ca2+. Diffraction
data were collected at beamline 14.1 of the Helmholtz-Zentrum Berlin (35),
processed with XDS (36) and programs of the CCP4-suite (37). Phasing was
performed by MR using the human furin–inhibitor complex structure [PDB
ID code 4RYD (6)] and PHASER (38); the model was built in COOT (39) and
refined in PHENIX (40). Structural alignments and graphics were prepared in
PYMOL (www.pymol.org) (see SI Materials and Methods for further details).
Principal Component Analysis. A PCA was carried out on Furin’s crystallo-
graphic structures (SI Materials and Methods).
MD Simulations. The MD simulations were performed using the GROMACS
(41) (v5.0.3) molecular simulation package (see SI Materials and Methods for
further details).
Note Added
During preparation and revision of our report, PDB ID struc-
ture 4Z2A (10.2210/pdb4z2a/pdb; www.rcsb.org/pdb/explore.
do?structureId=4Z2A) became available, which also shows a
structure of human unliganded furin.
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SI Materials and Methods
Protein Expression and Purification.Details regarding the plasmids,
expression system, and purification procedure used for production
of human furin were described previously (17). In short, the protein
was expressed by transient transfection of human embryonic kidney
cells, comprised of the catalytic and P-domains, and was purified
by a three-step chromatographic procedure consisting of immo-
bilized metal-affinity chromatography, immobilized inhibitor affinity
chromatography, and gel-permeation chromatography. To increase
the yield of recombinant protein, a modified expression and har-
vesting procedure was applied. For this purpose, transfection was
carried out in 150 × 25-mm tissue culture dishes (Falcon) with
0.17 mL/cm2 DMEM supplemented with 2% (vol/vol) FBS, and
5 mM CaCl2. Twenty-four hours postinduction the medium was
exchanged by DMEM without FBS but supplemented with 2 mM
CaCl2. Finally, conditioned medium was harvested after 72 h of
cultivation. Medium containing the recombinant protease was
centrifuged at 4,500 × g for 20 min, filtered with a Durapore
membrane (Merck-Millipore) of 0.45-μm pore size, and concen-
trated ∼25-fold in a stirred pressure-based concentration cell
(Merck-Millipore) with an Omega 10K ultrafiltration membrane
(Pall). Concentrated medium was flash-frozen in liquid nitrogen and
stored at −80 °C. Immediately before purification, concentrated
medium was thawed in a water bath at 25 °C and centrifuged at
4,500 × g for 20 min. For purification by immobilized metal-affinity
chromatography, the supernatant was diluted 1:4 in 100 mM Tris/
HCl, pH 8.0, 500 mM NaCl, and 5 mM CaCl2.
Inhibition Assays. To biochemically probe for the inhibitory po-
tency of typical, nonspecific covalent inhibitors of serine proteases
against different proteases, DFP, AEBSF, and PMSF were in-
cubated at 1, 2.5, and 0.5 mM, respectively, with subtilisin
(250 μg/mL; ∼9.3 μM), trypsin (5 μg/mL; ∼0.2 μM), and furin
(170 μg/mL; ∼3.3 μM) in 100 mMHepes, 5 mM CaCl, 0.5% Triton
X-100, pH 7.0 for 1 h at 37 °C. Subsequently, 1 μL was transferred
into an activity test in 100 mM Hepes/NaOH, 5 mM CaCl2, 0.5%
Triton X-100, pH 7.0 at 37 °C using 0.2 mM of the substrates
Z-Gly-Gly-Leu-AMC (subtilisin), H-Gly-Arg-AMC (trypsin), and
pGlu-Arg-Thr-Lys-Arg-AMC (furin). The increase in fluorescence
was analyzed by linear regression (Tecan Infinity M1000, excitation
380 nm, emission 460 nm).
The resulting activity data are given in nanomoles of AMC per
hour: for DFP: subtilisin: 4.64 ± 0.08 vs. <0.04, trypsin: 23.82 ±
0.71 vs. 0.35 ± 0.02, furin: 7.33 ± 0.47 vs. 7.67 ± 0.32; for AEBSF:
subtilisin: 5.37 ± 0.30 vs. <0.04, trypsin 23.40 ± 0.71 vs. 0.29 ± 0.02,
furin: 7.52 ± 0.63 vs. 6.65 ± 0.33; for PMSF: subtilisin: 4.85 ± 0.21
vs. <0.04, trypsin: 23.83 ± 0.85 vs. 0.48 ± 0.02, furin: 7.19 ± 0.60 vs.
7.62 ± 0.18.
Crystallization, Crystal Soaking, and Structure Determination. Crystals
of human furin were grown in sitting drops mixing equal volumes
of the protein solution (∼9 mg/mL) and crystallization solution
[100 mMMes, 200 mM K/NaH2PO4, pH 5.5–6.0, 3–4 M NaCl and
3% (vol/vol) DMSO]. The reservoir contained 3–4 M NaCl. To
study inhibitor binding in situ, the crystals were soaked over-
night with 100 mM Mes, 200 mM K/NaH2PO4, pH 6.0, 3.0 M
NaCl, 1 mM CaCl2, and 3% (vol/vol) DMSO supplemented with
0.2 mM inhibitor MI-52 (#26 in ref. 4). To study the structure of
furin in the presence of EDTA, crystals were washed with
100 mM Mes, 200 mM K/NaH2PO4, pH 6.0, 3.0 M NaCl, and
3% (vol/vol) DMSO and soaked for 1 h with the same solution
supplemented with 5 mM EDTA. To study inhibitor binding to
furin in the presence of EDTA, crystals were washed with 100 mM
Mes, 200 mMK/NaH2PO4, pH 5.0, 3.16 M NaCl, and 3% (vol/vol)
DMSO, soaked for 1 h with the same solution supplemented with
5 mM EDTA, and finally overnight supplemented with 5 mM
EDTA and 0.2 mM MI-52. To study calcium binding at defined
concentrations in the absence of phosphate by anomalous dif-
fraction, crystals were washed in 100 mM Mes, pH 6.0, 100 mM
KCl, 3.16 mM NaCl, and 3% (vol/vol) DMSO and soaked for 1 h
with the same solution supplemented with 2 mM EDTA. To
complex the crystals with Ca2+, they were washed with 100 mM
Mes, pH 6.0, 100 mM KCl, 3.16 mM NaCl, and 3% (vol/vol)
DMSO supplemented with the respective concentration of CaCl2
and soaked in the same solution. Two Ca2+ concentrations were
applied: (i) in the presence of 1 mM CaCl2 (high Ca
2+) the
crystals were washed 1× and soaked 2× for 0.5 h and 1× for 1 h;
(ii) in the presence of normally 1 nM CaCl2 (low Ca
2+) the crystals
were washed 2× and soaked 4× for 0.5 h and 1× for 1 h. Because
of the high concentrations, the inherent calcium content of the
used chemicals contributes mainly to the overall calcium con-
centration of the soaking solution with very low Ca2+ supple-
mentation. The maximum calcium contribution as a result of
contamination from the used chemicals was calculated to be
142 μM, according to the specifications of the manufacturers.
The drop size for washing and soaking of the crystals was always
∼1 μL. To measure diffraction data at 100 K, the crystals were
cryo-protected by supplementation of the respective reservoir or
soaking solutions with 13.1% (vol/vol) ethylene glycol and flash-
cooled in liquid nitrogen. Diffraction data were collected at the
BESSY-II beamline 14.1 of the Helmholtz-Zentrum Berlin (35).
Data processing was performed with XDS (36) (v10/2014) via the
XDSAPP interface (v1.0) and programs of the CCP4-suite (37)
(CCP4 v6.3.0, CCP4 interface v2.2.0). The Phase Problem was
solved by MR using the structure of human furin [PDB ID code
4RYD (6)] as a search model in PHASER (38). Model building
was carried out in COOT (39) (v0.6.2). PHENIX (40) (v1.9-
1692) was used for refinement. Refinement parameters of the
MI-52 were generated with the PRODRG-server. Simulated
annealing composite-omit electron-density maps were calcu-
lated in PHENIX, whereby the omitted region comprised 2.5%
of the model. PYMOL (www.pymol.org) was used for structure
alignments and molecular graphics.
Principal Component Analysis. A PCA was carried out considering
furin’s crystallographic structures reported in this publication:
(i) furin unliganded state (PDB ID code 5JXG), (ii) furin un-
liganded state soaked with EDTA (PDB ID code 5JXI), (iii) furin
with MI-52 bound (PDB ID code 5JXH), and (iv) furin soaked with
EDTA and with MI-52 bound (PDB ID code 5JXJ); together with
previously reported structures of the human enzyme [PDB ID codes
4RYD (6), 4OMC (17), and 4OMD (17)]. The analysis was per-
formed considering a subset of 191 Cα atoms to allow a direct
comparison with subtilisin Carlsberg, a homologous bacterial pro-
tease. Furin residues considered were: 121–124, 133–162, 193–206,
213–226, 235–242, 248–256, 286–297, 308–343, 350–361, 364–401,
and 423–436; which correspond to the following subtilisin Carlsberg
residues: 5–8, 12–41, 63–76, 82–95, 106–113, 120–128, 146–157,
168–203, 204–215, 217–254, and 262–275. The projections of the
human furin structures (mentioned above), the murine furin
structure [PDB ID code 1P8J (16)], and two subtilisin Carlsberg
structures [PDB ID codes 1CSE (26) and 3UNX (25)] are shown
in Fig. 3. The PCA analysis was conducted using the GROMACS
(41) subroutines g_covar and g_anaeig.
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MD Simulations. The starting coordinates of the modeled systems
were taken from the refined crystallographic structures (PDB IDs
codes 5JXG and 5JXH), as well as from the comparable subtilisin
structures [PDB ID codes 1CSE (26) and 3UNX (25)]. The furin
unliganded EDTA-soaked (PDB ID code 5JXI) structure was
used as a model to evaluate the influence of an empty Ca2+-(II)
ion pocket. Four additional systems were established from the
experimental data. Two of these systems were after removing the
coordinates of the bound ligand from furin and substilisin-
complexed structures (PDB ID codes 5JXG and 1CSE), a third
one was to evaluate the influence of protonating Asp258 in a
furin unliganded EDTA-soaked (PDB ID code 5JXI) structure,
and the last one was to assess the influence of setting Thr367’s χ1
angle at 60° as the initial conformation in the furin unliganded
structure (PDB ID code 5JXH). Crystallographic waters and
ions located at the ion binding sites were included in the simu-
lated models of furin and substilisin. All systems were simulated
with GROMACS 5.0.3 (41) using the AMBER99SB-ILDN all-
atom force field in an explicit water-solvent scheme in periodic
boundary conditions. The topology and force-field parameter
files for the ligand MI-52 were generated with ACPYPE (42).
The protein protonation was performed with Molprobity (43).
The water molecule model used was that based on the Trans-
ferable Intermolecular Potential with three sites, TIP3P. The
solvent also included sodium chloride (NaCl) at 0.15 mM plus a
small surplus of ions for electric charge neutralization. The long-
range electrostatic interactions were computed using the fast
particle-mesh Ewald setting, using a grid spacing of 1.2 Å. The
van der Waals and short-range electrostatic interactions were
computed using a cut-off of 1.1 Å for both parameters. The
neighbor list was updated every 20 steps using the Verlet cut-off
scheme. All bonds were constrained using LINCS, enabling a
simulation time step of 2 fs.
The following start-up protocol was applied to all modeled
systems: First, two consecutive minimization processes, with
(i) 1,000 steps under the steepest descendant algorithm and
(ii) 500 steps using conjugate gradient algorithm. Subsequently,
the following two simulations were carried out to equilibrate the
system at 300 K: (i) 500 ps in the canonical ensemble at 300 K
using a V-rescale thermostat (τ = 0.1 ps) and (ii) 500 ps in the
equilibrium isobaric (NTP) ensemble using Berendsen pressure
coupling at 1 bar (τ = 2.0 ps). During these processes, a restraint
constant of 1,000 kJ·mol−1·nm−2 was applied to all protein heavy
atoms and to all main-chain heavy atoms for the equilibrium
isochoric (NVT) and NPT equilibrations, respectively. An addi-
tional 500 ps were simulated within NTP conditions without re-
straints. Finally, 100 ns of MD simulations were performed in the
NTP ensemble using the Parrinello–Rahman barostat with no
restraints. The protocol was repeated five and four times, starting
from the minimized structures with a new assignment of velocities
for the furin and subtilisin systems, respectively. The rmsd analysis
(Fig. S7) indicates equilibrated systems with stabilizations at
around 1.2 Å and 0.8 Å for furin and substilisin simulations, re-
spectively. To perform all of the reported analysis, the first 20 ns
of each simulation were discarded.
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Fig. S1. Structural analysis of furin in its unliganded vs. its MI-52–bound states. (A) Plot of the Cα-displacement values of the Cα atoms covering all amino acids of
furin (intervals <0.3 Å, 0.3–0.8 Å, and >0.8 Å are highlighted in cyan, yellow, and magenta, respectively). (B) Mapping of the respective values to the molecular
surface and colored according to A. (C) Cartoon representation colored according to A. Bound ions are shown as light gray (Na+) and dark gray (Ca2+) spheres.
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Fig. S2. Electron-density maps observed for the active-site residues and the alignment template of human furin. Stereo panels show the structures in stick
representation. The 2Fo–Fc simulated annealing composite-omit electron density maps are given as blue-colored mesh, which is contoured at 1.0 σ. (A) Un-
liganded furin. (B) Furin complexed with MI-52. (C) Unliganded furin in presence of EDTA. (D) Furin in presence of EDTA and complexed with MI-52.
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Fig. S3. Stereo representation of the structural comparison of substrate binding by furin and subtilisin Carlsberg. Detailed view of the alignment template
and the active-site residues of inhibitor-bound furin (protein: gray-colored stick model; inhibitor: gray-colored ball-and-stick model), unliganded furin (yellow-
colored stick model), unliganded subtilisin (light orange-colored stick model), and eglin-c (shown P5–P1 segment Ser-Pro-Val-Thr-Leu) bound subtilisin (protein:
light green-colored stick model; inhibitor: dark green-colored ball-and-stick model). (A) Structural alignment of selected residues of unliganded furin and
inhibitor-bound furin. Steric clashes between bound inhibitor/substrate and unliganded furin are highlighted as red line patterns around the respective atoms.
(B) Structural alignment of unliganded subtilisin and inhibitor-bound subtilisin. Important interactions of the active-site residues and between the alignment
template and the inhibitor are highlighted as gray and yellow dashes, respectively. (C) Structural alignment of inhibitor-bound subtilisin and furin. Important
homologous amino acids of the proteases are labeled in green (subtilisin) and gray (furin).
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Fig. S4. Rotameric states from MD simulations. Histograms are computed from five independent runs of each simulated system: unliganded furin (red), furin
with inhibitor MI-52 (blue), unliganded furin in the presence of EDTA (green), unliganded furin with Thr367’s χ1 initially set at 60° (black), unliganded furin in
the presence of EDTA and with Asp258 protonated (yellow). For residues Ser368 (A), Thr367 (B), Asp258 (C), and Asn295 (D) the measured quantity is the χ1
dihedral-angle, whereas for Gly255 (E) it is the ψ dihedral-angle. The information is split into two panels for clarity. The Upper panel contains plots from the
simulations of unliganded furin, furin with inhibitor, and unliganded furin in the presence of EDTA structures; the Lower panel contains plots corresponding to
simulations of unliganded furin with Thr367’s χ1 initially set at 60° and unliganded furin in the presence of EDTA with Asp258 protonated. Each curve rep-
resents an average histogram (solid lines) with 1 SD as upper limit (error bar). The averages were computed from five independent runs. The values in each
inset correspond to the values found in the crystallographic structures.
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Fig. S5. Substrate-induced conformational changes of the sodium site in furin. Stereo panels show a superposition of selected residues of unliganded furin
(yellow, protein: stick model; nonbonded atoms: spheres) and inhibitor-bound furin (gray, protein: stick model; inhibitor: ball-and-stick; nonbonded atoms:
spheres). (A) Superposition of the unliganded inhibitor-bound states. (B and C) Electron-density maps observed for the sodium binding site. Sodium ions and
water molecules are given as big and small spheres, respectively. The 2Fo–Fc simulated annealing composite-omit electron-density maps are given as blue-
colored mesh and are contoured at 1.0 σ. (B) Unliganded furin. (C) Furin complexed with MI-52.
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Fig. S6. Binding of calcium to furin and its structural effects. (A) Bar diagram of the anomalous signal observed for the calcium binding sites at high (1 mM)
and low (formally 1 nM, but see SI Materials and Methods for details) Ca2+ concentrations as well as in the presence of EDTA. (B–D) The coordinating amino
acids are given for Ca binding sites Ca-I (B), Ca-II (C), and Ca-III (D) as stick model (yellow carbons correspond to high calcium concentration, cyan carbons
correspond to the presence of EDTA) together with selected water molecules (red spheres). The Ca2+ ions (green spheres) are shown together with the
anomalous electron-density map (countoured at 6.0 σ and given as orange mesh) at high calcium concentration or in presence of EDTA. At low Ca2+-con-
centration, Ca2+-(III) is displaced by Na+ (purple sphere). (E) Stereo representation of the superposition of EDTA and MI-52 soaked furin (purple carbons, purple
inhibitor) with non-EDTA–treated furin (gray). Selected hydrogen bonds are highlighted as dashes according to Fig. 2. Coordinative bonds of Ca2+-(II) are
highlighted as gray dashes. Calcium ions and water molecules are represented by large and small spheres, respectively (coloring according to the carbon atoms
of the respective structures). (F) Superposition of unliganded furin (yellow) and additionally EDTA-treated unliganded furin (cyan). Basically, identical struc-
tural alterations as shown in Fig. 2A are observed. Steric clashes with the superposed inhibitor (according to Fig. 2A and Fig. S4) and with N295 in its inhibitor-
bound conformation are highlighted as red line pattern. Coordinative bonds of Ca2+-(II) are highlighted as yellow dashes. Calcium ions and water molecules are
represented by large and small spheres, respectively (coloring according to the carbon atoms of the respective structures).
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Fig. S7. Rmsd curves for the simulated systems. In the panels are shown the average rmsd curves (solid lines) with 1 SD as upper and lower limits (error bars).
The averages were computed out of five and four independent runs for furin and substilisin systems, respectively. In all cases, the starting protein-fold
is preserved.
Table S1. Data collection and refinement
Dataset Unliganded Unliganded + inhibitor EDTA EDTA + inhibitor
Resolution range (Å) 46.1–1.8 (1.91–1.80) 43.1–2.0 (2.12–2.00) 46.2–2.0 (2.12–2.00) 46.1–2.0 (2.12–2.00)
Unit cell (P6522) (Å): a, c 132.0, 155.6 131.8, 155.6 132.4, 155.7 132.1, 155.6
Rsymm* (%) 9.6 (62.3) 10.8 (57.5) 11.6 (59.5) 13.6 (78.8)
<I/sig(I)> 13.4 (2.8) 13.5 (3.1) 14.3 (3.0) 11.9 (2.3)
Completeness (%) 99.1 (98.3) 99.2 (98.8) 98.9 (99.1) 98.9 (98.7)
Observations: total/unique 364,023/73,616 266,429/53,872 268,857/54,336 266,967/53,880
Rwork/Rfree 15.4/17.3 15.7/18.6 15.8/18.5 16.7/18.9
Nonhydrogen atoms 4,263 4,204 4,126 4,130
Protein/Inhibitor/ions/solvent 3,608/–/12/643 3,608/54/8/534 3,597/–/9/520 3,608/54/8/460
B-factors (Å2)
Overall/Wilson plot 20.9/24.2 23.5/26.4 22.1/24.6 24.5/27.0
Protein/inhibitor/ions/solvent 19.0/–/24.3/32.6 22.1/17.3/22.7/33.4 20.7/–/26.9/31.5 23.5/19.1/27.0/33.1
Rmsd bond length (Å) 0.007 0.007 0.007 0.007
Rmds bonded B-factors (Å2) 3.6 3.7 4.2 4.0
Values of the highest resolution shell are given in parentheses.
*Rsymm=ΣhΣljIhl-<Ih>j/ ΣhΣlj<Ih>j.
Table S2. Statistics for diffraction datasets collected at low energy to analyze Ca2+-binding
Dataset Unliganded low energy Low Ca2+ low energy EDTA low energy
Wavelength (Å)/energy (eV) 2.07/6,000 2.07/6,000 2.07/6,000
Resolution range (Å) 47.2–2.4 (2.58–2.44) 47.2–2.6 (2.73–2.58) 47.2–2.6 (2.73–2.58)
Unit cell (P6522) (Å): a, c 132.1, 155.4 132.4, 155.4 132.1, 155.3
Rsymm* (%) 11.0 (58.0) 10.6 (55.3) 9.9 (47.7)
<I/sig(I)> 10.1 (2.1) 11.3 (2.2) 12.0 (2.6)
Anomalous completeness (%) 99.1 (97.4) 98.4 (96.5) 98.2 (96.0)
Observations: total/unique 186,624/56,144 159,820/47,320 159,072/47,096
Initial model refinement
Rwork/Rfree 18.6/21.8 17.0/20.5 17.3/20.7
Values of the highest resolution shell are given in parentheses.
*Rsymm=ΣhΣljIhl-<Ih>j/ ΣhΣlj<Ih>j.
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